Using radiation to help immunotherapy work again in metastatic cancer
Part of Cancer clinical trials.
This study tests whether targeted radiation can help your immune system respond to immunotherapy again if your cancer has stopped responding. You would continue your current immunotherapy and receive a few focused radiation doses to one tumor site.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your cancer has spread to other parts of the body and is a solid tumor (not blood cancer)
- You have been on an anti-PD1 immunotherapy for at least 6 months and the cancer recently started growing again
- You have at least one tumor that can be treated with stereotactic radiation and another that can be measured by scans
- Your general health is good enough that you can care for yourself (performance status 0 or 1)
- You do not have a pacemaker or other active implanted device that could interfere with radiation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding targeted radiation to your metastatic tumors can help your immunotherapy work better. It is for people with advanced solid tumors that have spread to 3-10 spots and who have been on immunotherapy for at least 3 months.
This study tests whether a focused, high-precision type of radiation can control many cancer spread-out spots (“metastases”) at the same time, while keeping side effects acceptable. It may help people with many metastases live longer or have better disease control by aiming treatment at every treatable spot.
This trial tests whether a precise type of radiation can control cancer that has spread to a limited number of sites (1–10) while you also have the main tumor. It aims to improve outcomes by treating all visible cancer spots with stereotactic ablative radiotherapy.
This study looks at combining radiation therapy with immunotherapy for advanced breast cancer that has spread or cannot be surgically removed. The goal is to see if adding radiation after treatment helps improve outcomes.
This Phase 2 study tests whether adding a very focused type of radiation to standard drug treatment can better control metastatic breast cancer. It is for people whose cancer is only progressing in one spot, seen on a PET scan.
This trial tests combining two types of radiation therapy with an immunotherapy drug for people with advanced solid tumors that have spread or come back. The goal is to see if this approach can help when standard treatments have stopped working or aren’t an option.
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.